The present invention is a recombinant vector encoding and expressing at least three or more costimulatory molecules. The recombinant vector may additionally contain a gene encoding one or more target antigens or immunological epitope thereof. The synergistic effect of them costimulatory molecules on the enhanced activation of T cells is demonstrated. The degree of T-cell activation using recombinant vectors containing genes encoding three costimulatory molecules was far greater than the sum of recombinant vector constructs containing one costimulatory molecule and greater that the use of two costimulatory molecules. Results employing the triple costimulatory vectors were most dramatic under conditions of either low levels of first signal or low stimulator to T-cell ratios. This phenomenon was observed with both isolated CD4+and CD8+T cells. The recombinant vectors of the present invention are useful as immunogenes and vaccines against cancer and pathogenic micro-organisms, and in providing host cells, including dendritic cells and splenocytes with enhanced and antigen-presenting functions.

 
Web www.patentalert.com

< Method for the selective survival or selective growth of a target cell by the use of a conjugate, its use in therapeutics and/or diagnostics and the preparation of said conjugate

< Production of an immunovariant strain of Eimeria maxima contributes to strain cross-protection with other Eimeria maximas

> Delta-aminolevulinic acid for prevention and treatment of infection by pathogenic microorganisms and parasite

> Phosphorus binder for treatment of kidney disease

~ 00223